syros.com - SYRS EV/Sales Multiple

Official company branding of Syros Pharmaceuticals Inc. (SYRS)

Syros Pharmaceuticals (SYRS) is developing a gene control system for the treatment of cardiac and oncological pathologies. This chart in the GURU.Markets terminal illustrates the company's enterprise value to revenue (EV/Revenue) valuation, where the indicator determines the metric's magnitude. This price action reflects the stable operation of production lines and a strategic partnership with medical centers to develop targeted drugs against leukemia.

Syros Pharmaceuticals, Inc. (SYRS) EV/Sales Multiple: for the period 07/04/2022 - 11/20/2026

Financial and market metric breakdowns for Syros Pharmaceuticals, Inc. (SYRS)

Fundamental company valuation:SYRS (Syros Pharmaceuticals)
Mass-produced product of syros.com

Developing precision medicines for leukemia therapy requires colossal investments, which is why the market value of Syros Pharmaceuticals (SYRS) is often decoupled from current earnings. This indicator compares the total enterprise value to revenue, excluding the impact of debt and leverage, allowing for an objective assessment of asset overvaluation and the risk of capital freeze through changes in the company's enterprise value-to-revenue multiple.

Competitor analysis for Syros Pharmaceuticals

TEM (tempus.com) - Company Value to Revenue Ratio|qiagen.com (QGEN) - Enterprise Value-to-Revenue Ratio|Ionis (IONS) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Repligen|Avidity (RNA) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple CRSP|Total Company Value-to-Revenue Ratio GeneDx|Enterprise Value-to-Revenue Ratio Ultragenyx RARE|Total Company Value-to-Revenue Ratio Beam Therapeutics (BEAM)|SRPT: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Twist Bioscience|TXG (10x Genomics) - Company Value to Revenue|Intellia Therapeutics, Inc. (NTLA) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Stoke Therapeutics Inc|BLFS: Business Value to Revenue|Company Value to Revenue WVE (Wave Life Sciences Corp)|Total Company Value-to-Revenue Ratio Maze Therapeutics Corp|Sionna Therapeutics Inc - Company Value to Revenue|PRME (primemedicine.com) - Enterprise Value to Sales Volume|TSHA - Enterprise Value-to-Revenue Ratio|QURE (uniQure) - Company Value to Revenue Ratio|MeiraGTx Corp (MGTX) - Enterprise Value-to-Revenue Ratio|Regenxbio - Business Value to Revenue|Enterprise Value-to-Revenue Ratio solidbio.com|Enterprise Value-to-Revenue Multiple ocugen.com OCGN|EV/Sales Multiple PACB|Benitec - Company Value to Revenue Ratio|Enterprise Value-to-Revenue Ratio Design Therapeutics DSGN|EV/Sales Multiple Rocket Pharmaceuticals RCKT|Enterprise Value to Sales Volume 4D Molecular Corp|LXEO: Enterprise Value-to-Revenue Ratio|KRRO (Korro Bio, Inc) - Company Value to Revenue|Editas Medicine (EDIT) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Silence Therapeutics Inc.|Company Value to Revenue Ratio PRQR (proqr.com)|Enterprise Value-to-Revenue Ratio Codexis Bio (CDXS)|EV/Sales Multiple sangamo.com (SGMO)|Enterprise Value-to-Revenue Ratio nautilus.bio NAUT|Total Company Value-to-Revenue Ratio Metagenomi, Inc (MGX)|Precision BioSciences Inc. - EV/Sales Multiple|GBIO - EV/Sales Multiple|BOLD: EV/Sales Multiple|Company Value to Revenue Ratio XCUR|Enterprise Value-to-Revenue Ratio Imunon|Phio Pharmaceuticals - Enterprise Value to Sales Volume|Enterprise Value-to-Revenue Ratio Mustang Bio, Inc. (MBIO)|Total Company Value-to-Revenue Ratio TransCode Therapeutics, Inc.|Enterprise Value-to-Revenue Ratio Bionano Genomics BNGO|Business Value to Revenue APDN|BLUE - Enterprise Value-to-Revenue Ratio|Enterprise Value to Sales Volume IPA|Omega Therapeutics, Inc. (OMGA) - Enterprise Value-to-Revenue Ratio|Singular Genomics Corp (OMIC) - EV/Sales Multiple|RGLS (Regulus Therapeutics, Inc.) - EV/Sales Multiple|Company Value to Revenue Telesis Bio (TBIO)|EV/Sales Multiple TCON|UBX - Enterprise Value-to-Revenue Multiple